Market Newsdesk

CHICAGO, Dec. 08, 2020 (GLOBE NEWSWIRE) — Today, HIMSS announces the launch of a new Office of Scientific Research, a learning community for health sector stakeholders around the globe. The Office of Scientific Research (OSR), aims to focus on the creation of robust empirical evidence around digital health, delivering critical – and actionable – insights and best practices that will power the future of healthcare.

Digital health transformation varies widely across the globe with different goals to achieve and populations to serve within every health system. With this variability, it is critical that insights, knowledge and evidence of clinical, financial and operational improvement be accessible and shared to drive improved outcomes as digital health transformation accelerates.

“With the velocity information is shared today, key intelligence and best practices are constantly being defined and redefined,” said Reid Oakes, Executive Vice President of Analytics for HIMSS. “The future of healthcare relies on ensuring the information we have at our fingertips, is evaluated and validated to drive the innovation that will create pathways for broadening health equity and improved clinical, financial, and operational outcomes. The HIMSS Office of Scientific Research was created to convene the best health sector partners, harness intelligence and make it globally accessible to power the future of healthcare.”

Initial areas of focus for OSR include:

• Operational performance of health systems
• Equity in access to health services and equity as it relates to health outcomes
• Health outcomes and the personalization of healthcare delivery
• Impact of digital health ecosystems on health workforce outcomes
• Global impact of digital capacity and health system performance across jurisdictions

To learn more about OSR and how your organization can partner with HIMSS, connect with us.

About HIMSS

Healthcare Information and Management Systems Society, Inc. (HIMSS) is a global advisor and thought leader supporting the transformation of the health ecosystem through information and technology. As a mission-driven non-profit, HIMSS offers a unique depth and breadth of expertise in health innovation, public policy, workforce development, research and analytics to advise global leaders, stakeholders and influencers on best practices in health information and technology. Through our innovation engine, HIMSS delivers key insights, education and engaging events to healthcare providers, governments and market suppliers, ensuring they have the right information at the point of decision.

Headquartered in Chicago, Illinois, HIMSS serves the global health information and technology communities with focused operations across North America, Europe, the United Kingdom, the Middle East and Asia Pacific. Our members include more than 80,000 individuals, 480 provider organizations, 470 non-profit partners and 650 health services organizations.

Karen D. Groppe

Senior Director, Strategic Communications
Mobile 312.965.7898  | Twitter @Karen_D_Groppe

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zosano Pharma Corporation (NASDAQ: ZSAN) from February 13, 2017 through September 30, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zosano Pharma Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application (“NDA”) included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 28, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Loop Industries, Inc. (NASDAQ: LOOP) from September 24, 2018 through October 12, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Loop Industries, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Loop scientists were encouraged to misrepresent the results of Loop’s purportedly proprietary process; (2) Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) as a result, the Company was unlikely to realize the purported benefits of Loop’s announced partnerships with Indorama and Thyssenkrupp; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

WASHINGTON, Dec. 08, 2020 (GLOBE NEWSWIRE) — HIV has become an aging issue now that more than half of people living with HIV/AIDS in the U.S. are 50 or older. Thanks to advancements in treatment, people with HIV can now live for decades but longevity with HIV is relatively new, under-explored, and under-resourced, and the HIV/AIDS and aging services networks operate almost totally separately, with few age-specific services. Grantmakers In Aging, a national membership organization of philanthropies, created Moving Ahead Together: A Framework for Integrating HIV/AIDS and Aging Services to help end the painful isolation and improve the care of older people living with HIV.

“People living with HIV age into a sort of no-man’s land that can be a lonely and potentially dangerous place,” said John Feather, PhD, CEO of Grantmakers In Aging (GIA). “Aging services and HIV services both deliver excellent care but have no history of working together, and people aging with HIV can get lost. The need for greater coordination, expertise sharing, and inclusion has been strongly affirmed by leaders in both sectors, and, importantly, by people who are themselves aging with HIV/AIDS.”

A Blueprint for
I
ntegrat
ing
Aging and HIV
Se
rvices

The framework covers three areas: social complexities and challenges, including low awareness of the issue and the stigma and social isolation many older people with HIV face; the need for a whole-person approach to coordinate medical, mental, and behavioral health care with social and psychosocial support; and updating state and federal policies.

For example, the framework calls for efforts to:

• Help geriatricians and primary care providers build their knowledge of HIV in older people, including testing, prevention, sexual health counseling, and considering HIV in diagnosis.
  • About 17% of new HIV infections happen among people age 50+.
• Incorporate principles of trauma-informed care and increase cultural competency of providers and staff in all care settings, including senior centers and long-term care, to create a welcoming and inclusive atmosphere.
  • Trauma, stigma, and fear of rejection or being “outed” in an unfamiliar care setting can drive older people living with HIV away from treatment and into isolation.

• Help HIV specialists gain expertise in geriatrics issues (multiple chronic conditions, geriatric syndromes, medication management, cognitive impairment, etc.) and in HIV’s effect on the aging process.
• Co-locate or coordinate HIV and aging services, including social work and social services, to help people manage complex care needs.
• Improve access to mental and behavioral health care, and educate providers that trauma is part of the experience of many people aging with HIV, including long-term survivors.

• Address psychosocial challenges, such as isolation, and social determinants of health, such as food insecurity, unstable housing, disability, and poverty.
• Prepare Medicare, Medicaid, and long-term services and supports (LTSS) to meet the medical and social needs of people aging with HIV.
• Expand caregiving options and research for HIV-specific concerns about cognitive decline, dementia, and Alzheimer’s disease.
• Make existing policies more inclusive, such as adding aging issues to the federal Ending the HIV Epidemic (EHE) plan and reconsidering eligibility for aging services.
  • The accepted age for onset of aging in people with HIV is 50; but eligibility for many federal and state aging programs starts at 60 or older.

These recommendations were guided by the distinguished Moving Ahead Together steering committee, comprised of leaders in the aging and HIV service sectors, and by participants in a virtual summit.

A Racial and Social Justice Issue

The Framework also examines outdated assumptions about HIV, social justice issues such as racial disparities in prevalence and access to care, and parallels between the AIDS epidemic and COVID-19.

Respecting the Denver Principles of ensuring meaningful involvement by people with HIV in decisions that affect them, the report also includes first-person reflections and video interviews with older people living with HIV, and all featured artwork was created by older people living with HIV.

GIA’s multi-year Moving Ahead Together initiative and this report are supported by a grant from Gilead Sciences. For more information, please click here.

About Grantmakers In Aging
(GIA)
Grantmakers In Aging is a national membership organization of philanthropies. Believing a society which is better for older adults is better for people of all ages, GIA acts as a relevant and responsive network, resource, and champion, amplifying the voices of older people and issues of aging. Our vision is of a just and inclusive world where older people are fully valued, recognized, and engaged in ways that matter. Learn more at www.GIAging.org.

Media Contact

Elliott Walker ([email protected]) 

London, UK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Sutikki, the children’s entertainment company behind the popular UK series Moon & Me, has inked a new pact with US-based educational technology company Digital Dream Labs (DDL), to create, develop and distribute animated and live action content based on the company’s ground-breaking robot duo Cozmo and Vector.

The journey from best-selling toy brand to entertainment franchise starts today with the premiere of the first animated featurette which debuts on the newly launched Cosmo & Friends YouTube channel Click Here  The hub will host a steady flow of innovative and creative content that will further explore Digital Dream Labs’ revolutionary robot creations. 

Sutikki’s initial focus will be on Cozmo, an expressive little robot with a mind of its own. Endowed with a one-of-a-kind personality that evolves and learns over time, one look at its big blue eyes reveals Cozmo’s star potential.  Cozmo blazed a trail when it launched in 2017 earning the top spot for the best-selling toy on Amazon U.S. two years in a row and the best-selling toy on Amazon in the UK and France in 2017 (Source: One Click Retail).

Sutikki plans a comprehensive content campaign, initially on its dedicated YouTube channel. The short-form videos will showcase the robot’s marketing and commercial potential, tapping into the production company’s ability to showcase IP on a global scale. Sutikki will leverage its experience and expertise in building highly engaging brand franchises that speak to the discerning, tech savvy kids of today.

Beyond plans for new video content, the partnership includes the development of innovative merchandising and coincides with Digital Dream Labs’ pre-order for updated versions of both of their popular consumer robots.  The pre-order list opened on 20^th November 2020 ahead of the holiday season with the new robots hitting retail in Spring 2021.

“We’re looking forward to introducing Cozmo and friends to the world,” says Hannah Mungo, CEO, Sutikki. “Cozmo is an extraordinary character who is not only an educational asset and friend for children, but also full of play and exploration. We are extremely excited to tap into the unique characteristics of DDL’s amazing robot line through creative content and bold new consumer products that will form the blueprint for what is certain to be one of entertainment’s most exciting future franchises.”

Digital Dream Labs is a global leader of creating hands-on educational technology for children of all ages. The high-tech firm specializes in creating engaging, language and system-agnostic products that connect with kids of all ages. Imbued with personality and spirit, the line of robots are more than simple educational tools and have already gained an online following that sets the stage for a successful evolution into the entertainment realm.

“It’s been a real pleasure for our team to watch the animators capture Cozmo’s unique personality,” says co-founder and CEO of Digital Dream Labs, Dr. Jacob Hanchar. “We’re really excited to see this partnership grow and know that families around the world will welcome Cozmo into homes across many different interactive touchpoints.”

Sutikki has offices in Atlanta and Los Angeles. To learn more visit www.sutikki.com.

For more information about Digital Dream Labs and their educational technology games and consumer robots, visit www.digitaldreamlabs.com.

Attachments

• CAF1
• cozmo-lifestyle-02